Last updated: August 23, 2026
Ultravate is a mature branded topical corticosteroid containing halobetasol propionate 0.05%. Sun Pharmaceutical Industries markets the product in the United States. Its commercial position is supported by physician familiarity and high-potency treatment demand, but its financial trajectory is constrained by generic halobetasol competition, limited treatment duration, low differentiation and the absence of separately reported brand revenue.
Ultravate is unlikely to be a material standalone growth driver for Sun Pharma. Its value is more consistent with a mature dermatology portfolio asset that generates incremental revenue through prescriptions, formulary access and channel presence.
What is Ultravate used for and which formulations are marketed?
Ultravate is indicated for the topical treatment of plaque psoriasis and corticosteroid-responsive dermatoses. The active ingredient, halobetasol propionate, is a super-high-potency topical corticosteroid. The product is generally used for short courses because prolonged exposure increases the risk of local and systemic corticosteroid effects.[1]
| Product attribute |
Ultravate profile |
| Active ingredient |
Halobetasol propionate |
| Strength |
0.05% |
| Therapeutic class |
Super-high-potency topical corticosteroid |
| Main indication |
Plaque psoriasis and steroid-responsive dermatoses |
| U.S. marketer |
Sun Pharmaceutical Industries, Inc. |
| Dosage forms |
Cream, ointment and lotion presentations have been marketed |
| Treatment duration |
Typically limited to short courses, commonly up to two weeks depending on product labeling |
| Regulatory pathway |
New Drug Application product with generic ANDA competition |
| Commercial maturity |
Mature branded prescription product |
The lotion format is commercially important because it improves spreadability over large or hair-bearing areas compared with an ointment. The ointment remains relevant for thick plaques and highly keratinized lesions. Creams compete in general dermatology prescribing and retail pharmacy channels.
How large is the Ultravate market?
Ultravate-specific revenue is not separately disclosed in Sun Pharma’s public financial reporting. The company reports aggregate revenue by geography and business segment rather than by individual mature topical brands.[2]
The addressable market is divided among:
- Branded and generic halobetasol products.
- Other high-potency topical corticosteroids.
- Nonsteroidal topical therapies.
- Systemic and biologic treatments for moderate-to-severe psoriasis.
- Over-the-counter and lower-potency steroid products for less severe disease.
Ultravate’s economic exposure is therefore determined more by its share of the broader topical corticosteroid market than by an independently reported franchise.
Sun Pharma’s United States business remains strategically important, but its growth is increasingly associated with specialty products, differentiated dermatology products and complex generics. A mature halobetasol brand is unlikely to have the pricing power or growth rate of newer products such as ILUMYA, WINLEVI or other specialty dermatology assets.[2]
What drives demand for Ultravate?
Demand is supported by several durable factors:
- Continued prevalence of psoriasis, eczema and other inflammatory skin diseases.
- Physician preference for high-potency topical treatment before escalation to systemic therapy.
- Low treatment cost relative to biologics.
- Broad availability through dermatology and primary-care channels.
- Familiarity with halobetasol among prescribers.
Demand is limited by the product’s potency restrictions. Ultravate is not intended for unrestricted long-term use, large body-surface-area treatment or routine maintenance therapy. Once inflammation is controlled, physicians often step down to lower-potency corticosteroids, nonsteroidal products or intermittent treatment.
What is the financial trajectory for Ultravate?
Ultravate’s financial trajectory is best characterized as mature, stable to declining on a standalone branded basis, with limited upside from formulation mix or distribution expansion.
Revenue outlook
The principal revenue pressures are:
- Generic substitution.
- Wholesale and pharmacy purchasing concentration.
- Formulary restrictions.
- Rebates and gross-to-net deductions.
- Low switching costs among topical corticosteroids.
- Limited treatment duration.
- Availability of therapeutically similar alternatives.
The product may maintain prescription demand even as branded net sales decline because halobetasol remains clinically useful. That distinction matters: volume can remain resilient while branded pricing and market share deteriorate.
Sun Pharma does not identify Ultravate revenue as a separate line item. The brand’s contribution is therefore embedded within the company’s U.S. formulations business. Investors should not treat total U.S. dermatology revenue as a proxy for Ultravate performance because Sun Pharma’s specialty portfolio includes products with materially different growth, pricing and exclusivity profiles.[2]
Margin outlook
Topical corticosteroids can have attractive manufacturing economics because they are chemically synthesized, non-biologic products with established production processes. However, mature products face price compression from generic suppliers and pharmacy benefit manager negotiations.
Ultravate’s gross margin is likely higher than that of an unbranded commodity generic if Sun Pharma retains brand recognition and payer access. The margin advantage narrows when:
- Multiple ANDA holders compete for the same prescriptions.
- Pharmacies substitute generic halobetasol automatically.
- Payers place the brand on a non-preferred tier.
- Sun Pharma uses rebates to preserve formulary access.
- Contract manufacturers or competitors offer lower acquisition costs.
When did Ultravate lose exclusivity?
Ultravate is a legacy small-molecule product and no longer benefits from meaningful new-drug exclusivity. Its current commercial position depends on brand recognition, formulation availability, manufacturing execution and distribution rather than regulatory exclusivity.
The original product patents and any historical regulatory exclusivity periods are no longer the primary commercial barrier. Generic halobetasol products are available in the United States in multiple dosage forms, including creams, ointments and lotions.[3]
| Exclusivity category |
Current commercial relevance |
| Original composition-of-matter protection |
Expired or no longer commercially controlling |
| New-drug exclusivity |
Expired |
| Paragraph IV risk |
Primarily historical for legacy products |
| Formulation protection |
Limited practical protection against broad generic substitution |
| Biosimilar exclusivity |
Not applicable |
| Orphan-drug exclusivity |
Not applicable |
What patents protect Ultravate today?
Ultravate does not have the patent profile of a recently launched specialty drug. Its active ingredient is an established corticosteroid, and the core commercial risk is generic substitution rather than a pending patent cliff.
Potentially relevant intellectual-property categories include:
- Formulation patents.
- Vehicle or excipient combinations.
- Lotion delivery systems.
- Manufacturing process claims.
- Method-of-use claims.
- Labeling-related exclusivity.
These categories generally provide narrower protection than a valid composition-of-matter patent. A formulation patent may protect a specific vehicle, concentration or manufacturing approach without preventing competitors from marketing halobetasol in another approved dosage form.
The most important diligence point is that Ultravate’s economic moat does not appear to depend on a broad, live patent covering halobetasol itself. The FDA Orange Book remains the controlling source for current listed patents and regulatory exclusivity associated with an approved reference product.[4]
What generic entry risks exist for Ultravate?
Generic entry risk is high because halobetasol is a conventional topical small molecule with an established clinical and manufacturing history.
Generic competition
Generic halobetasol products can compete through:
- Lower acquisition cost.
- Automatic pharmacy substitution.
- Payer formulary preference.
- Multiple dosage forms.
- Therapeutic equivalence under FDA approval standards.
For topical products, generic competition can be more complex than simple active-ingredient matching because vehicle composition, emulsion characteristics, particle size and skin delivery can influence performance. FDA’s topical product guidance recognizes that local dermatologic products may require product-specific equivalence analysis.[5] That technical complexity can slow or limit some entrants, but it does not eliminate long-term generic pressure.
Paragraph IV challenges
A Paragraph IV certification is most consequential when an ANDA applicant challenges a still-active Orange Book patent. For a mature product such as Ultravate, the commercial importance of a new Paragraph IV challenge is lower than it would be for a recently launched drug because generic versions are already available.
A future entrant could still challenge formulation or method-of-use patents if any remain listed. The likely business impact would be incremental price pressure and additional generic supply, not a first generic event.
How does Ultravate compare with competing dermatology drugs?
Ultravate competes across different therapeutic and economic segments.
| Product category |
Examples |
Competitive effect on Ultravate |
| Generic high-potency steroids |
Generic halobetasol, clobetasol, fluocinonide |
Direct price and substitution pressure |
| Branded steroid combinations |
Calcipotriene/betamethasone products |
Offer combination therapy and maintenance positioning |
| Nonsteroidal topicals |
Tapinarof, roflumilast, ruxolitinib |
Reduce reliance on chronic topical steroids |
| Biologics |
IL-17, IL-23 and TNF inhibitors |
Draw moderate-to-severe psoriasis patients away from topical monotherapy |
| Lower-potency steroids |
Triamcinolone, betamethasone and hydrocortisone products |
Compete for less severe or maintenance treatment |
Ultravate retains an advantage in rapid anti-inflammatory effect and low cost. It is disadvantaged in chronic maintenance, large-area treatment and steroid-sparing therapy.
What is the FDA regulatory status of Ultravate?
Ultravate is an FDA-approved prescription topical corticosteroid. The product’s regulatory risk is primarily labeling, manufacturing and post-market safety compliance rather than approval uncertainty.
Important label limitations include:
- Use for a limited duration.
- Avoidance of unnecessary treatment of large body-surface areas.
- Caution regarding hypothalamic-pituitary-adrenal axis suppression.
- Risk of local adverse effects such as skin atrophy.
- Pediatric restrictions that vary by formulation and label.
The FDA has not created a biosimilar pathway for Ultravate because halobetasol is a chemically synthesized small molecule, not a biologic. Competitors enter through the ANDA pathway rather than through abbreviated biosimilar applications.
What manufacturing and intellectual-property barriers affect Ultravate?
Manufacturing barriers are moderate, not high.
The active ingredient is a conventional synthetic corticosteroid. The main technical requirements involve:
- Consistent active-ingredient dispersion.
- Stable semisolid or lotion formulation.
- Microbiological control.
- Preservative performance where applicable.
- Packaging compatibility.
- Uniform dosing and application characteristics.
- Demonstration of pharmaceutical equivalence and bioequivalence where required.
Lotion and semisolid products can present greater development complexity than oral tablets. Differences in vehicle composition can affect release, spreadability and skin penetration. These issues may reduce the number of immediate competitors for a particular formulation, but generic availability across the halobetasol category remains a structural constraint.
Which companies challenge Ultravate commercially?
The competitive set includes generic manufacturers with halobetasol products and branded dermatology companies selling alternative topical therapies. Competition is less concentrated around a single challenger than around a broad field of generic and therapeutic substitutes.
The most relevant competitors are:
- Generic halobetasol manufacturers.
- Manufacturers of generic clobetasol and fluocinonide.
- Companies selling calcipotriene/betamethasone combinations.
- Developers of nonsteroidal psoriasis products.
- Specialty pharmaceutical companies selling biologics.
Sun Pharma’s own dermatology portfolio can create both strategic support and internal substitution. A physician may prescribe a mature topical steroid for mild disease and reserve a higher-value branded specialty product for patients requiring longer-term or more advanced treatment.
What licensing deals affect Ultravate?
No major recent licensing transaction is central to Ultravate’s commercial value. The product is an established branded asset rather than a newly partnered innovation.
The relevant commercial arrangements are more likely to involve:
- Wholesale distribution.
- Pharmacy benefit manager contracting.
- Specialty and retail channel access.
- Generic manufacturing and supply agreements.
- Portfolio-level dermatology partnerships.
These arrangements can affect net price and market access, but they do not create the type of milestone-based revenue trajectory associated with a newly licensed drug.
What generic launch scenarios are most likely?
Base case
Generic halobetasol continues to take share, while Ultravate remains available as a branded option. Prescription volume remains clinically relevant, but net sales decline gradually because of substitution and pricing pressure.
Downside case
Payers move the brand to unfavorable formulary tiers, generic supply expands and pharmacy substitution rises. Ultravate becomes a low-volume branded product with limited pricing power.
Resilience case
Sun Pharma preserves distribution, secures favorable payer placement and benefits from patients or physicians who prefer the branded lotion or a specific formulation. Revenue stabilizes at a smaller base, but the product does not return to high-growth status.
Key Takeaways
- Ultravate is a mature halobetasol propionate 0.05% topical corticosteroid marketed by Sun Pharma.
- Its principal indications are plaque psoriasis and other corticosteroid-responsive dermatoses.
- Product-specific revenue is not separately disclosed by Sun Pharma.
- The brand no longer benefits from meaningful new-drug exclusivity.
- Generic halobetasol and other potent topical steroids create high substitution risk.
- No biosimilar risk exists because Ultravate is a small-molecule product.
- Formulation and manufacturing complexity may slow individual generic launches but does not create a durable category-wide barrier.
- Financial performance is likely stable to declining on a branded basis, with limited growth potential.
- Ultravate’s strategic value is as a mature dermatology portfolio product, not as a major standalone growth asset.
FAQs
Is Ultravate still patented?
Ultravate’s original product exclusivity is no longer commercially controlling. Any current formulation or method-of-use patents must be assessed through the FDA Orange Book and relevant patent records.
Is generic Ultravate available?
Yes. Generic halobetasol propionate is available in the United States in topical dosage forms, including cream, ointment and lotion products.
Does Ultravate compete with biologics?
Yes, indirectly. Biologics treat moderate-to-severe psoriasis and can reduce the use of topical corticosteroid monotherapy, although Ultravate remains relevant for localized or less severe disease.
Who owns the Ultravate brand?
Sun Pharmaceutical Industries markets Ultravate in the United States. The product is part of Sun Pharma’s broader dermatology and U.S. formulations portfolio.
Can Ultravate become a growth product again?
A major return to growth is unlikely without a materially differentiated formulation, expanded indication, stronger channel economics or a strategic repositioning. The current product is exposed to mature-market generic competition.
References
- U.S. Food and Drug Administration. (2023). Ultravate (halobetasol propionate) lotion prescribing information.
- Sun Pharmaceutical Industries Limited. (2024). Annual report 2023-24.
- U.S. National Library of Medicine. (2024). DailyMed: Halobetasol propionate topical products.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (2022). Pharmacokinetic-based approaches for supporting alternative methods of demonstrating bioequivalence of topical dermatologic drug products.
